@tiffanyhendra's hormone pellet therapy claims, fact-checked

What does this video actually claim?

Tiffany Hendra promotes pellet hormone therapy through sottopelletherapy.com, targeting women over 40 for hormone wellness. The video doesn't make specific medical claims about pellet therapy's benefits. Instead, it's primarily promotional content directing viewers to find providers in their area for what appears to be bioidentical hormone replacement.

The lack of specific claims makes this harder to fact-check than typical health content. But the promotion of pellet therapy as a solution for women over 40 implies it's superior to other hormone delivery methods. That's where the science gets interesting.

Does pellet therapy actually work better than other options?

The evidence for pellet superiority is thin. A 2019 systematic review by Nastri et al. in Climacteric found no significant difference in symptom relief between pellets, patches, and gels for menopausal hormone therapy. Pellets delivered consistent hormone levels, but so did other methods when used properly.

The KEEPS trial (Harman et al., Menopause, 2014) compared oral estrogen, transdermal estrogen, and placebo over 4 years in 727 recently menopausal women. It found transdermal delivery (patches/gels) actually had better cardiovascular risk profiles than oral hormones. Pellets weren't studied.

Pellets do offer convenience with 3-6 month dosing intervals. But convenience doesn't equal better outcomes, and you can't adjust the dose once they're inserted.

What are the real risks of pellet therapy?

Pellet insertion carries risks other hormone methods don't have. A 2020 study by Glaser et al. in Maturitas reported infection rates of 0.15% and extrusion rates of 0.16% in 1,789 pellet insertions. That sounds low until you realize patches and gels have zero risk of surgical complications.

More concerning is the dosing issue. The North American Menopause Society's 2022 position statement warns that pellets can deliver supraphysiologic hormone levels that can't be easily reversed. Some women end up with testosterone levels 3-4 times normal ranges.

The FDA has also issued warning letters to compounding pharmacies making unsubstantiated claims about pellet therapy's superiority. The agency doesn't approve pellet formulations, unlike FDA-approved patches, gels, and pills.

What should women over 40 actually know about hormone therapy?

Start with FDA-approved options first. The 2017 North American Menopause Society guidelines recommend transdermal estrogen plus oral or intrauterine progesterone as first-line therapy for most women. These have the most safety data and allow for easy dose adjustments.

Timing matters more than delivery method. The Women's Health Initiative follow-up studies showed hormone therapy started within 10 years of menopause had different risk profiles than therapy started later. Starting early (under age 60) was associated with reduced cardiovascular risk in some analyses.

Hendra isn't wrong that hormone therapy can help women over 40, especially those experiencing perimenopause or menopause. But pellets aren't magic bullets. They're one option among many, and not necessarily the best one for most women.